期刊文献+

VEGF反义寡核苷酸与顺铂联合治疗抑制裸鼠骨肉瘤的生长 被引量:2

VEGF Antisense Oligonucleotides in Combination with DDP Inhibited the Growth of Osteosarcoma Nude Model
暂未订购
导出
摘要 目的探讨血管内皮生长因子(VEGF)反义寡核苷酸和顺铂单用或联用对裸鼠骨肉瘤生长的抑制作用。方法制备BALC/C裸鼠皮下骨肉瘤模型24只,随机分为4组:VEGF反义寡核苷酸治疗(ASODN)组、顺铂治疗(DDP)组、联合治疗(ASODN+DDP)组和对照组,每组6只。接种MG-63人成骨肉瘤细胞后24 h内采用瘤内注射和腹腔给药的方式,以VEGF反义寡核苷酸或(和)顺铂进行治疗;观察各组裸鼠肿瘤的生长情况、裸鼠的一般情况与生存期。断颈处死裸鼠,测量肿瘤体积大小,称量肿瘤的重量。结果VEGF-ASODN治疗组、DDP治疗组和联合治疗组裸鼠骨肉瘤的生长均受到不同程度抑制,抑瘤率分别为44.56%、53.69%和86.80%,以联合治疗组的疗效最佳。结论VEGF反义寡核苷酸与顺铂联用比单用顺铂可更好地抑制骨肉瘤的生长,两者联用可发挥协同抗瘤效应。 Objective To study the inhibitory effect of VEGF antisense oligonucleotides or/and DDP on the growth of Osteosarcoma Nude model. Methods The Osteosarcoma cells were cultured and implanted subcutaneously into 24 nude mice model which were subsequently divided into 4 groups : VEGF ASODN group, DDP group, combined group and control group. The different treatments were given respectively at 24 hours after cell inoculation. The weight and volume of subcutaneous tumors were measured. Result The growth inhibitory rate in VEGF - ASODN group was 44.56% ,53.69% in the DDP group,and 86.80% in the combined group. The combined group which was treated with VEGF -ASODN and DDP showed more effective inhibition than the VEGF - ASODN group or the DDP group respectively. Conclusion The growth of Osteosarcoma nude model can be inhibited by VEGF antisense oligonueleotides and DDP respectively. Better inhibitory effect can be obtained if VEGF - ASODN and DDP are combined in use.
出处 《南华大学学报(医学版)》 2009年第1期36-38,共3页 Journal of Nanhua University(Medical Edition)
基金 湖南省卫生厅课题资助项目(4-04-WS-B2004-089)
关键词 血管内皮生长因子 顺铂 反义寡核苷酸 骨肉瘤 VEGF Antisense oligonucleotides DDP osteosarcoma
  • 相关文献

参考文献5

二级参考文献17

共引文献33

同被引文献39

  • 1邱蔚六.口腔颌面外科学[M].6版.北京:人民卫生出版社,2009:217-218.
  • 2邱蔚六.口腔颌面外科学[M].第6版.北京:人民卫生出版社,2009:231.
  • 3Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metatasis-correlation in invasive breast carcinoma [J]. New Engl J Med, 1991, 324(1): 1-8.
  • 4Usman Saeed M, Batra R, Qureshi F, et al. Reflux of drug during intra-vitreal anti-VEGF therapies [J]. Semin Ophthalmol, 2011, 26(6): 357-360.
  • 5Ueta T, Mori H, Kunimatsu A, et al. Stroke and anti-VEGF therapy[J]. Ophthalmology, 2011, 118(10): 2093-2093.e2.
  • 6Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo [J]. Cancer Res, 1999, 59(4): 895-900.
  • 7Bruns C J, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in viva survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases[J]. Cancer, 2000, 89(3): 488-499.
  • 8Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin- expressing breast carcinoma cells [J]. Cancer Res, 2001, 61(15): 5736-5740.
  • 9Bravo R, Frank R, Blundell PA, et al. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta [J]. Nature, 1987, 326(6112): 515-517.
  • 10Hsieh TC, Burfeind P, Laud K, et al. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials [J]. Int J Oncol, 1999, 15(2): 245-252.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部